Company intelligence / Profile preview

EndoVigilant

Ownership: Private
Development stage: Preclinical

Overview

EndoVigilant has developed an artificial intelligence-enabled computer-aided detection platform to assist with polyp and adenoma identification during colonoscopies. In a multicenter randomized clinical trial ("AI-SEE"), the technology did not show a statistically significant improvement in adenoma detection rate compared to standard colonoscopy; however, it was associated with increased identification of larger and nonpolyploid polyps when used with certain setups. No adverse events were reported during the study[4].

Therapeutic areas: OncologyGastroenterology
Modalities: DeviceArtificial intelligence (AI)-enabled software (for endoscopy video analysis)
Industry: Digital Health Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships identified; academic collaboration noted below.

Beyond the preview

Go deeper on EndoVigilant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoVigilant.

Explore the full profile